This compound is widely used in the development of antibody-drug conjugates (ADCs), which are targeted cancer therapies. It serves as a linker that connects the cytotoxic drug to the antibody, ensuring precise delivery to cancer cells while minimizing damage to healthy tissues. The structure includes a cleavable peptide sequence (Val-Cit) that is specifically recognized and cleaved by enzymes such as cathepsin B, which are highly active in the tumor microenvironment. This selective cleavage releases the cytotoxic agent directly at the tumor site, enhancing the therapeutic efficacy and reducing systemic toxicity. Its application is critical in improving the safety and effectiveness of cancer treatments.